INTRODUCTION
There is a strong positive association between hereditary hemochromatosis and the HLA-A3 alloantigen. This was shown in a study of 152 unrelated patients with the disease (1) . The frequency of HLA-A3 was 72% in patients and 21% in controls, giving a relative risk value of 9.5. Close linkage of the HLA locus to the hemochromatosis locus was demonstrated in pedigree studies (2) (3) (4) (5) (6) . We obtained a total lod score in eight pedigrees of +9.8 at a recombination fraction of 0.0 (7). This close genetic linkage indicates that recombination between the two loci will occur infrequently.
Therefore, HLA genotyping of siblings of patients with hemochromatosis can be used to identify abnormal homozygotes (a pair ofabnormal alleles), heterozygotes (one normal and one abnormal allele), and normal Received for publication 26 October 1979 and itn revised form 15 January 1980. homozygotes (a pair of normal alleles). All male homozygotes over the age of 20 yr had transferrin saturations > 79% and hepatic iron concentrations > 400 gg/100 mg wet liver (major iron load). Transferrin saturation was abnormally increased (51-77%) in 31% of male heterozygotes and in 17% of female heterozygotes (minor iron load).
Idiopathic refractory sideroblastic anemia (IRSA)' is not known to be familial (8 (8) .
The leukocyte counts were 3,800-8,500/mm3. The platelet counts were 250,000-427,000/mm3. None of the patients were alcoholic. None received iron therapy or transfusions before evaluation of the iron status, except for SA-G-II-2, who re-ceived 10 transfutsions. The control population for the study of HLA alloantigens coi)sisted of 318 descendants of Utah pioneers.
Relative risk (RR) wvas determinied from the formula, RR = (P+)(C-)/(P-)(C+), where P is the numiber of patients and C the number of controls positive or negative for the HLA-A3 alloantigen (10) . The frequency of the HLA-A3 antigen in the patient and in the control population were compared by chi-square analysis with Yates' correction. Published methods were uised for the HLA typing (11) , for the evaluationi of iron status (12) , and for the hemiiatologic measuremenits (13) .
RESULTS
The HLA haplotypes, hematologic characteristics, and iron statuis of the patients with IRSA are presented in Table I .
Transferrin saturation was increased in all seven patients. Serum ferritin was increased in five of the seven. Urinary iron excretion after deferoxamine was increased in four out of five.
Five of the seven patients carried an HLA-A3 alloantigen (frequency, 0.71). The frequency ofthis antigen in the control population was 0.255. The relative risk was 7.3. The difference between the two groups was statistically significant (P = 0.02).
Three siblings ofthe proband (11-2) in pedigree SA-B were studied along with his wife and four children (Fig. 1) . The proband had no clinical manifestations of hemochromatosis. The three siblings (II-1, 4, and 5) of the proband (II-2) carried the A3,B14 haplotype in common with the proband. The transferrin saturation of two of the siblings (11-4, 11-5) was increased (minor iron load). Their serum ferritin values were 174 (II-1), 124 , and 62 (11-5) ng/ml. Because we have observed a transferrin saturation > 51% in only one out of96 genetically normal subjects (a pair of normal alleles) (7), (7) . Four siblings of the proband in pedigree SA-A were studied along with his wife and three children (Fig. 2) . The proband with sideroblastic anemia had clinically manifest hemochromatosis with skin pigmentation and histologic evidence of early cirrhosis of the liver. Hepatic parenchymal cell stainable iron was grade 4 (normal, 0-1) and the hepatic iron concentration was 602 ,g/100 mg wet liver (normal, 0-29). His brother (II-3) had clinically manifest hemochromatosis with skin pigmentation and histologic evidence of cirrhosis of the liver but not sideroblastic anemia. His iron values were: serum iron, 336 ,ug/100 ml; transferrin saturation, 100%; serum ferritin, 3,300 nglml; urinary iron excretion after deferoxamine, 16.0 mg/24 h; hepatic parenchymal cell stainable iron, grade 4; and hepatic iron concentration 430 ,ug/100 mg wet liver. Because II-3 had clinically manifest hemochromatosis and carried the HLA-A3,B12 and Ai,Bw35 haplotypes, the presumption is that these two haplotypes each carried an allele for hemochromatosis. The proband (8, 9, 14) . The studies reported in this paper relate to a specific and clearly defined subset ofpatients with sideroblastic anemia, those with IRSA (8) . Only seven patients with this specific type of sideroblastic anemia were available to us for study. A larger population of patients needs to be studied to confirm the association with HLA-A3.
The frequency of the HLA-A3 alloantigen in this small group of unrelated patients with IRSA (71%) is similar to that observed in hereditary hemochromatosis (72%) (1). The significance of this association is strengthened by our finding clinically manifest hemochromatosis in a sibling of one proband and abnormalities in iron metabolism (minor iron load) in two siblings of a second proband. This suggests that patients with IRSA carry a single allele for hemochromatosis and tha this allele plays a role in the increased iron loadin* observed in this form of anemia. However, because sideroblastic anemia is not a feature of hereditary hemochromatosis and since most heterozygotes for hemochromatosis do not develop sideroblastic anemia, it is apparent that a second factor, the sideroblastic factor, is required for the development ofanemia. IRSA has not been observed in more than one member of a family in our studies or by others (8, 9) . Whether the Hemochromatosis and Sideroblastic Anemia I I sideroblastic factor is genetic or acquired cannot be stated from the limited informnation available. In any event, it seem,s that at least one allele for hemoclhromiiatosis and the sideroblastic factor are requiired for the expression of IRSA and that clinically m-anifest hemoclhromlatosis may develop in an occasional patient with only one allele for hemochromiatosis in the presence of the sideroblastic factor.
